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Introduction
Head and neck cancer (HNC) is the fifth most 
common cancer worldwide accounting for ap-
proximately 5% of all tumours1,2. Squamous cell 
carcinoma is the most common histotype (ap-
proximately 90%), and generally arises from the 
mucosa of the upper aerodigestive tract.
HNCs constitute a heterogeneous collection 
of tumors. This includes five main different 
subtypes according to the site of the primary tu-
mor: the nasopharynx, oropharynx, oral cavity, 
hypopharynx and larynx. Nevertheless, they are 
all characterized by a predominant route of loco-
regional metastasis through the lymphatic draina-
ge and by a relatively low proportion of distant 
hematogenous metastases.
The most important treatment modalities for 
HNC consist of surgery, radiotherapy (RT) and 
chemotherapy (CT). In recent years, due to impro-
vements in RT treatment delivery such as intensity 
and modulated RT (IMRT), as well as the incre-
asing use of more intensive altered fractionation 
schedules, radiochemotherapy (RT-CT) has beco-
me a valid alternative to radical surgery showing 
similar rates of locoregional control3,4. However, 
residual neck disease may be present in as many 
as 30-60% of patients after completion of RT-CT. 
For these patients, irrespective of the HNC stage, 
there seems to be a consensus in the literature fa-
voring immediate neck dissection, because of the 
very low probability of achieving disease control 
with salvage surgery when recurrence develops5-7. 
Abstract. – OBJECTIVE: To assess changes 
of CT perfusion parameters (ΔPCTp) of cervi-
cal lymph node metastases from head and neck 
cancer (HNC) before and after radiochemother-
apy (RT-CT) and their association with nodal tu-
mor persistence.
PATIENTS AND METHODS: Eligibility crite-
ria included HNC (Stage III-IV) candidates for 
RT-CT. Patients underwent perfusion CT (PCT) 
at baseline 3 weeks and 3 months after RT-CT. 
Blood volume (BV), blood flow (BF), mean transit 
time (MTT) and permeability surface (PS) were 
calculated. PET/CT examination was also per-
formed at baseline and 3 months after treatment 
for metabolic assessment. 
RESULTS: Between July 2012 and May 2016, 
27 patients were evaluated. 
Overall, only 3 patients (11%) experienced tumor 
persistence in the largest metastatic lymph node. 
A significant reduction of all PCTp val-
ues (p<0.0001), except MTT (from 6.3 to 5.7 s; 
p=0.089), was observed at 3 weeks post-RT-CT 
compared to baseline. All PCTp values includ-
ing MTT were significantly lower at 3-month fol-
low-up compared to baseline (p<0.05). More-
over, a statistical significant association was 
observed between nodal tumor persistence and 
high BF values (p=0.045) at 3 months after treat-
ment that did not occur for the other parameters.
CONCLUSIONS: Our preliminary findings show 
that all PCTp except MTT are significantly reduced 
after RT-CT. High BF values at 3 months post-RT-
CT are predictive of nodal tumor persistence. 
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Therefore, prior assessment of nodal tumor 
response is crucial due to the importance to re-
fer patients to surgery in case of partial response 
(PR) and to properly identify those who experien-
ced a complete response (CR) as they would not 
benefit from a neck dissection8. In this regard, an 
early detection of tumour persistence is desirable 
in determining a successful salvage surgery9.
In the current clinical practice, evaluation of no-
dal tumour response post-RT-CT is based on the 
combination of computed tomography (CT) and 
neck ultrasonography (US), reporting a negative 
predictive value of 95% and 81% and a positive 
predictive value of 82% and 84%, respectively. 
The fluoro-deoxy-glucose positron emission to-
mography (FDG-PET) can provide additional va-
lue by adding metabolic information to standard 
radiological imaging, achieving an excellent ne-
gative predictive value (95.1%) despite a low po-
sitive predictive value (75%) due to inflammatory 
changes10. As a consequence, interest is rising on 
new imaging technologies with the potential to 
more accurately evaluate tumour response in or-
der to identify “non-responder” patients who could 
benefit from salvage surgery as soon as possible. 
Diffusion-weighted MR imaging (DW-MRI) al-
lows for differentiation of post RT-CT inflamma-
tion and necrosis reporting a negative and positive 
predictive values of 96% and 70%, respectively11. 
These results are found despite being hampered by 
several limitations such as relatively poor spatial 
resolution, susceptibility to artefacts and modest 
reproducibility of apparent diffusion coefficient 
(ADC) values12,13. Perfusion computed tomography 
(PCT) can provide quantitative information on the 
status of tumor microcirculation that might reflect 
early treatment response or predict outcome. Hen-
ce, it has been proposed as a potential additional 
tool for noninvasive functional assessment of tre-
atment response14-19. Although no consensus has 
yet been reached about the optimal timing of PCT 
imaging, several experimental studies on both hu-
mans and animal models have shown the ability of 
PCT to detect changes less than 1 month after or 
even within days of starting therapy (i.e. well be-
fore a reduction in tumor size can be demonstrated 
in conventional morphological CT imaging)20-22. 
Compared with other imaging techniques such as 
FDG-PET or MRI, PCT retains the advantages of 
high spatial resolution, fast imaging time and a li-
near relationship between tissue iodine concentra-
tion and CT density. This feature can be exploited 
to derive absolute quantitative PCT data from de-
convolution algorithms14. 
In this study, we prospectively evaluated the 
changes in CT perfusion parameters (ΔPCTp) of 
the largest cervical adenopathy, measured both at 
3 weeks and 3 months after RT-CT and compared 
with pre-treatment values (Primary Endpoint). 
Moreover, we sought to find an association betwe-
en ΔPCTp values and biopsy proven tumor persi-
stence in the largest cervical adenopathy (Secon-
dary Endpoint).
Patients and Methods
This study was conducted according to the 
Declaration of Helsinki. All patients gave their 
written consent to all diagnostic and therapeutic 
procedures. 
Study Design
Enrollment criteria, PCT image acquisition 
protocol and treatment details have been repor-
ted in full in a previous paper of ours23. In brief, 
patients affected by Stage III-IVB HNC (undiffe-
rentiated nasopharyngeal type or squamous cell 
carcinoma arising from oropharynx, oral cavity, 
larynx or hypopharynx) who were candidates to a 
radical RT-CT, were enrolled. 
In addition to the standard diagnostic workup, 
all patients underwent a contrast-enhanced CT 
examination of the head and neck for morphologi-
cal evaluation of the largest adenopathy (as detai-
led in the dedicated subsection) and a whole body 
[18F]FDG-PET/CT scan. To the purpose of the 
PCT analysis, the largest adenopathy was defined 
as the cervical adenopathy with the largest maxi-
mum transverse diameter based on RECIST cri-
teria24. Then, PCT was repeated at 3 weeks (early 
evaluation) and 3 months (late evaluation) after 
completion of RT-CT, whereas [18F]FDG-PET/CT 
was repeated 3 months after RT-CT. In case of 
suspected tumor nodal persistence, an US-guided 
FNAC or FNAB was performed for cytological or 
histological confirmation. If confirmed, patients 
were referred to salvage neck nodal dissection un-
less in the presence of concurrent distant metasta-
ses. Thereafter, routine follow-up was performed 
based on current international guidelines25.
Perfusion CT Protocol
The PCT acquisition protocol was descri-
bed in detail in our previous paper23. All PCT 
studies were performed using a high-definition 
64-row CT scanner (Discovery CT750 HD®, 
General Electric, Milwaukee, WI, USA) opera-
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ting in axial mode with a toggling table tech-
nique, resulting in a z-axis coverage of 8 cm 
centered on the lesion site as assessed upon re-
view of preliminary morphological CT or MR 
images obtained for tumor staging26,27. All PCT 
datasets were transferred in DICOM format to 
a workstation (Advantage Windows v. 4.5, Ge-
neral Electric Milwaukee, WI, USA) equipped 
with a dedicated plugin (CT Perfusion 3) for 
calculation of blood flow (BF), blood volume 
(BV), mean transit time (MTT), and permeabi-
lity surface (PS) product based on a deconvolu-
tion, two-compartment algorithm14.
Circular regions of interest (ROI) were po-
sitioned inside the nodal tumor, as well as on 
the ipsilateral common or external carotid ar-
tery for sampling of the arterial input function 
needed to calculate the PCTp. ROIs were placed 
on the slice containing the largest lymph node 
section area so as to maximize the amount of 
sampled data per patient. ROI contours were 
kept at least 1 mm far away from node borders 
and care was taken to avoid macroscopic are-
as of tumor necrosis or calcification. All ROIs 
were identified independently by two radiolo-
gists with 10 and 3 years of experience in HN 
imaging, respectively, and by a radiation thera-
pist with 9 years of experience. Each PCT para-
meter is the average of the three measurements 
by the three readers.
Statistical Analysis
A descriptive analysis of data was carried out 
before performing inferential tests. Categorical 
data were described by frequency and continuo-
us data by mean and range. The normality of the 
distribution of BV, BF, MTT and PS was evalua-
ted using Kolmogorov-Smirnov test. Temporal 
variations of PCTp at baseline and at 3-week and 
3-month follow-up, were assessed using the Fri-
edman test and the two-tailed Wilcoxon test for 
multiple comparisons. Furthermore, temporal dif-
ferences of PCTp between patients with and wi-
thout tumor nodal persistence and/or recurrence, 
were evaluated using the two-tailed Mann-Whit-
ney. A p-value less than 0.05 was set as threshold 
for statistical significance. Statistical analysis was 
performed using software SPSS 24 (IBM, SPSS 
Inc., Armonk, NY, USA).
Results
Patient and Tumor Characteristics
Between July 2012 and May 2016, 37 patients 
were enrolled in our study. Among them, 27 pa-
tients were able to be evaluated for adenopathy 
response after RT-CT. Baseline patient and tumor 
characteristics are summarized in Table I. All da-
tasets were of diagnostic quality.
According to standard radiological RECIST 
criteria, at 3 months after treatment, 21/27 patien-
ts (78%) exhibited CR in the largest adenopathy 
and the remaining 6/27 patients (22%) exhibited 
PR. Indeed, the FDG-PET adenopathy response 
evaluation showed a CR in 23/27 patients (85%) 
and a PR in 4/27 patients (15%). Therefore, 2 pa-
tients had conflicting results of a radiological PR 
yet a metabolic CR. 
In total, 3 patients (11%) showed biopsy-proven 
tumor persistence in the largest adenopathy after 
treatment. Only one patient was classified with 
both a radiological and metabolic PR, while 2 pa-
tients had conflicting results of a radiological PR 
yet a metabolic CR. 
Finally, 2 patients underwent salvage neck dis-
section that confirmed the tumor persistence in the 
Table I. Patients and tumor characteristics.
Characteristics No. %
Site   
Nasopharynx 4 1 5  
Oropharynx 10 3 7  
Oral Cavity 4 1 5  
Hypopharynx 4 1 5  
Larynx 5 1 8  
Histology   
Squamous cell carcinoma 23 8 5  
Undifferentiated carcinoma 4 1 5  
T   
2 13 4 8  
3 3 1 2  
4 11 4 0  
N   
1 11 4 0  
2 12 4 5  
3 4 1 5  
Stage   
III 7 2 6  
IV 20 7 4  
IVA 13 6 5  
IVB 7 3 5  
Concurrent chemotherapy   
Cisplatin 40 mg/mq weekly 26 9 6  
Cisplatin 100 mg/mq every 21 days 1 4
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largest adenopathy, whereas one patient received 
systemic chemotherapy due to the concurrent pre-
sence of lung metastases. After a median follow-up 
of 20 months (range 9-56 months), no patients had 
a cancer-related death, whereas 1 patient died due 
to concurrent cardiovascular disease.
Variations of Tumor Perfusion 
Parameters of the Largest Adenopathy
The primary analysis was aimed at asses-
sing the ΔPCTp of the largest adenopathy in the 
post-treatment PCT (both at 3 weeks and at 3 
months) compared to the pretreatment values.
The mean and range values of the PCTp at ba-
seline, 3 weeks and 3 months after treatment are 
reported in Table II. Besides, the variations obser-
ved at each time-point (baseline, 3 weeks and 3 
months after treatment) with the significant p-va-
lues are shown in Table III. 
Overall, all PCTp values were significantly re-
duced at 3-weeks post RT-CT compared to baseli-
ne, except MTT (p=0.089). All PCTp values were 
significantly lower compared to baseline 3 mon-
ths after treatment. Moreover, a statistically si-
gnificant reduction of all PCTp values was found 
between the 3-week and the 3-month follow-up 
PCT examinations (Table III).
Association Between Variations of Tumor 
Perfusion Parameters (ΔPCTp) and Tumor 
Persistence in the Largest Adenopathy
A secondary analysis was aimed at assessing 
the relationship between adenopathy response 
and ΔPCTp both at 3 weeks and at 3 months after 
treatment. The results are reported in Table IV. 
As shown, patients who had tumor persisten-
ce in the largest adenopathy showed a higher 
mean value of BF compared to those who had a 
CR at 3 months after treatment (118.74 ml/100 
g vs. 33.76 ml/100 g; p=0.045). In comparison, 
the BF mean value did not show a significant 
association at 3 weeks after treatment in patien-
ts who had tumor persistence in the largest ade-
nopathy compared to those who experienced a 
CR (52.01 ml/100 g vs. 74.54 ml/100g; p>0.05). 
Indeed, no statistical significant association 
was observed between tumor persistence and 
changes of the other perfusion parameters both 
at 3 weeks and 3 months (p>0.05). 
Table II. Primary adenopathy perfusion parameters variations scores from baseline to post-treatment.
 BV (ml/100 g/min) BF (ml/100 g) MTT (s) PS (ml/100 g/min)
Baseline    
Mean 29.9 280.9 6.3 48.1
Range 2.7-117.9 50.3-902.4 2.3-7.19 6.9-184.1
3 weeks    
Mean 8.3 79.3 5.7 10.6
Range 0-62.1 0-556.6 0-21.1 0-60.1
3 months    
Mean 1.8 34.3 2.3 5.8
Range 0-19.5 0-287.1 0-16.1 0-44.8
Abbreviations: BV: Blood Volume; BF: Blood Flow; MTT: Mean Transit Time; PS: Permeability Surface.
Table III. Statistical significance of primary adenopathy 
perfusion parameters variations. 
Perfusion parameters p-value

















Abbreviations: BV: Blood Volume; BF: Blood Flow; MTT: 
Mean Transit Time; PS: Permeability Surface; PCTp: Perfu-
sion CT parameters.
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Discussion
The primary endpoint of this work was to 
investigate changes in the PCTp of the largest 
adenopathy from baseline to post RT-CT treat-
ment in order to evaluate their potential role as 
predictive factors of nodal tumor persistence 
in patients affected by HNC. To this purpose, 
both an early (3 weeks) and late (3 months) as-
sessment of ∆PCTp was performed after tre-
atment. Firstly, our results showed a signifi-
cant reduction of all PCTp values, except for 
MTT (from 6.3 to 5.7 s; p=0.089), early after 
treatment whereas all parameters showed a si-
gnificant late reduction (thus demonstrating a 
strong effect of RT-CT on such parameters). 
Our findings are in line with those reported 
in our previous paper regarding the primary 
tumor response23 as well as by similar studies 
published in the literature28-30. In particular, 
we had already observed a lower sensitivity of 
MTT compared to all other PCTp to predict re-
sponse early after treatment, whereas a signifi-
cant reduction of BV, BF and PS was reported 
both early and late after treatment. In this re-
gard, the trend toward reduction of those lat-
ter PCTp has already been explained as caused 
by the radiation and chemotherapy damage of 
low resistance neoangiogenetic vessels31,32. The 
study by Surlan-Popovic et al33 was the only 
research specifically investigating the changes 
of the primary tumor perfusion parameters du-
ring the course of RT reporting a significant 
reduction of BV and BF along with a nonsigni-
ficant variation of MTT and PS. 
To the best of our knowledge, this study is 
the first one specifically aimed at assessing the 
variations of PCTp values of cervical adeno-
pathies from before to after RT-CT, showing a 
potential role of all PCTp to predict treatment 
response. At a more detailed analysis, our pre-
liminary findings suggest a specific perfusion 
pattern of early treatment response characte-
rized by a significant reduction of BV, BF and 
PS together with a nonsignificant variation 
of MTT. In this context, our findings appear 
to be similar to those by Trojanowska et al34, 
who reported that metastatic lymphnodes from 
hypopharyngeal and laryngeal squamous cell 
carcinoma have significant higher BF, BV and 
PS than nonmetastatic ones. Moreover, a high 
baseline BF in primary HNC before RT-CT 
(followed by a significant decrease of BF and 
BV after treatment, such as in our study) was 
found to be 83.3% predictive of complete treat-
ment response. It suggests that BF may ref lect 
similar functional changes in metastatic lym-
phnodes35,36. 
While most investigations36-40 seem to agree 
in a significant treatment-related reduction of 
BV and BF, they also report contradictory fin-
dings regarding the changes in PS and MTT 
values, sometimes describing no significant 
variations in the post-treatment vs. the pretre-
atment values. 
These results add weight to the finding of our 
previous paper23, showing a superimposable 
trend of these parameters from before to after 
treatment. Based on the above observations, we 
believe that the role of MTT should be further 
investigated, as it might be pivotal in the in-
terpretation of tumor response both in primary 
site and in adenopathies. 
As a secondary endpoint of our paper, the 
ΔPCTp were associated to the tumor persisten-
ce cytologically or histologically confirmed in 
Table IV. Association between variations of perfusion parameters (ΔPCTp) and tumor nodal persistence. 
 Baseline – 3 months              Baseline – 3 weeks
Δ parameters  Mean p-value Mean p-value
       
BV (ml/100 g/min) NP 8.1 0.247 5.7 0.315
 NR 13.9  6.7 
BF (ml/100 g) NP 67.3 0.045 106.1 0.416
 NR 166.4  131.9 
MTT (s) NP 2.3 0.210 1.5 0.465
 NR 4.8  2.1 
PS (ml/100 g/min) NP 14.8 0.495 11.7 0.896
 NR 25.7  41.5  
Abbreviations: NP=nodal persistence NR=nodal remission.
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the largest adenopathy. We found that the persi-
stence of relatively high BF values at 3 months 
(a small reduction of BF between 3 months and 
baseline) was statistically associated to a high 
risk of tumor persistence. This is probably due 
to a high degree of tumor neovascularization in 
lymphnodes, which did not undergo a complete 
remission after treatment. In any case, we be-
lieve that the main limitation of this secondary 
analysis was the low number of events, as only 
3 patients (11%) had biopsy-proven tumor per-
sistence in the largest adenopathy whereas most 
patients showed complete CT remission.
Therefore, it is desirable that a greater sam-
ple size and higher number of events will lead 
to understanding the predictive role of other 
investigated parameters. Noteworthy, 2 of the 
3 nodal recurred patients (67%) in our study 
were FDG-PET negative, thus confirming the 
need to integrate morphological and functio-
nal data in advanced imaging technologies for 
a complete and accurate assessment of tumor 
response. 
Figures 1 and 2 report the imaging findings in 
a patient that summarizes our preliminary results. 
This patient was affected by a locally advanced 
hypopharynx cancer (Stage cT3N2b) that exhi-
bited both an early and late radiologic PR of the 
largest adenopathy associated with a progressive 
reduction of all PCTp (except MTT at 3 weeks) as 
well as a metabolic PR. 
Conclusions
We report the preliminary results of a pilot 
study aimed at investigating the potential role 
of a morphologic-functional integrated imaging 
technique in the interpretation of nodal tumor 
response after RT-CT. Although the real benefits 
of an early vs. delayed salvage neck surgery after 
RT-CT has not been proved yet, it will likely be 
Figure 1. A 64-year-old patient with squamous cell carcinoma of hypopharynx treated with exclusive RT-CT: (a) pre-tre-
atment morphologic CT image obtained from first-pass perfusion CT (PCT) data set. (b) pre-treatment metabolic FDG-PET 
shows abnormal tracer uptake in the IIA level adenopathy of the right side of the neck (SUV
max
18.25). Quantitative measu-
rement of pre-treatment PCT parameters revealed (a) BV=112.15 ml min-1, (b) BF=654.14 ml min-1 per 100 g, (c) MTT=11.22 
s and (d) PS=56.05 ml min-1 per 100 g.
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so in the future. As a consequence, early iden-
tification of partial or non-responder patients 
based on PCT findings might be extremely use-
ful in clinical practice to refer patients towards 
surgery as soon as possible in order to improve 
oncologic outcomes. Thus, longer follow-up and 
greater sample size will be useful to correlate the 
∆PCTp to the more important clinical outcomes, 
such as regional recurrence-free survival.
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